VERAXA Biotech (NASDAQ: VRXA) announced it has received Scientific Advice from Germany’s Paul-Ehrlich-Institute regarding the underlying biology and proposed non-clinical development plan for its lead proprietary BiTAC-TCE cancer therapy program. The company said the regulatory feedback provides greater clarity on its proposed development strategy and indicates that the agency understands the biological rationale behind its dual-targeting, conditionally active BiTAC-TCE platform, representing an early step in advancing the program toward clinical development.
This regulatory interaction is significant because it validates the scientific foundation of VERAXA’s BiTAC-TCE platform, which aims to selectively target cancer cells expressing both intended antigens while sparing healthy cells that express only one target. This dual-targeting mechanism could potentially reduce off-tumor toxicities commonly associated with T-cell engagers, improving the therapeutic index and patient outcomes. The Paul-Ehrlich-Institute, Germany’s federal authority for vaccines and biomedicines, is known for its rigorous evaluation of novel therapies, and its positive feedback suggests that the regulatory pathway for BiTAC-TCE is becoming clearer.
VERAXA also highlighted preclinical data presented at the American Association for Cancer Research Annual Meeting 2026 showing its lead BiTAC-TCE candidate selectively targeted cancer cells expressing both intended targets while sparing cells expressing only one target. According to the company, the studies demonstrated a favorable safety profile with efficacy comparable to a traditional T-cell engager, supporting the potential for an improved therapeutic index. These findings are critical as they address a major challenge in cancer immunotherapy: balancing potent anti-tumor activity with acceptable safety.
The implications of this announcement extend beyond VERAXA’s pipeline. If successful, the BiTAC-TCE platform could set a precedent for conditionally active bispecific T-cell engagers, encouraging further investment and research in targeted immune therapies that minimize systemic toxicity. The company’s progress also highlights the importance of early regulatory engagement to streamline development, potentially accelerating the timeline for clinical trials.
VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
For more information about this press release, visit https://ibn.fm/jpXam and for the latest news and updates relating to VRXA, visit the company’s newsroom at https://ibn.fm/VRXA.
